Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 62

1.

The Alzheimer's disease risk factors apolipoprotein E and TREM2 are linked in a receptor signaling pathway.

Jendresen C, Årskog V, Daws MR, Nilsson LN.

J Neuroinflammation. 2017 Mar 21;14(1):59. doi: 10.1186/s12974-017-0835-4.

2.

Is ApoE ɛ 4 a good biomarker for amyloid pathology in late onset Alzheimer's disease?

Ba M, Kong M, Li X, Ng KP, Rosa-Neto P, Gauthier S.

Transl Neurodegener. 2016 Nov 16;5:20. eCollection 2016. Review.

3.

Murine versus human apolipoprotein E4: differential facilitation of and co-localization in cerebral amyloid angiopathy and amyloid plaques in APP transgenic mouse models.

Liao F, Zhang TJ, Jiang H, Lefton KB, Robinson GO, Vassar R, Sullivan PM, Holtzman DM.

Acta Neuropathol Commun. 2015 Nov 10;3:70. doi: 10.1186/s40478-015-0250-y.

4.

Association of APOE with tau-tangle pathology with and without β-amyloid.

Farfel JM, Yu L, De Jager PL, Schneider JA, Bennett DA.

Neurobiol Aging. 2016 Jan;37:19-25. doi: 10.1016/j.neurobiolaging.2015.09.011. Epub 2015 Sep 28.

5.

Three dimensions of the amyloid hypothesis: time, space and 'wingmen'.

Musiek ES, Holtzman DM.

Nat Neurosci. 2015 Jun;18(6):800-6. doi: 10.1038/nn.4018. Review.

6.

Role of Apolipoprotein E in β-Amyloidogenesis: ISOFORM-SPECIFIC EFFECTS ON PROTOFIBRIL TO FIBRIL CONVERSION OF Aβ IN VITRO AND BRAIN Aβ DEPOSITION IN VIVO.

Hori Y, Hashimoto T, Nomoto H, Hyman BT, Iwatsubo T.

J Biol Chem. 2015 Jun 12;290(24):15163-74. doi: 10.1074/jbc.M114.622209. Epub 2015 Apr 27.

7.
8.

IL-10 alters immunoproteostasis in APP mice, increasing plaque burden and worsening cognitive behavior.

Chakrabarty P, Li A, Ceballos-Diaz C, Eddy JA, Funk CC, Moore B, DiNunno N, Rosario AM, Cruz PE, Verbeeck C, Sacino A, Nix S, Janus C, Price ND, Das P, Golde TE.

Neuron. 2015 Feb 4;85(3):519-33. doi: 10.1016/j.neuron.2014.11.020. Epub 2015 Jan 22.

9.

Amyloid-beta and Alzheimer's disease: the role of neprilysin-2 in amyloid-beta clearance.

Marr RA, Hafez DM.

Front Aging Neurosci. 2014 Aug 13;6:187. doi: 10.3389/fnagi.2014.00187. eCollection 2014. Review.

10.

Alzheimer's disease genetics: from the bench to the clinic.

Karch CM, Cruchaga C, Goate AM.

Neuron. 2014 Jul 2;83(1):11-26. doi: 10.1016/j.neuron.2014.05.041. Review.

11.

Interactions of metals and Apolipoprotein E in Alzheimer's disease.

Xu H, Finkelstein DI, Adlard PA.

Front Aging Neurosci. 2014 Jun 12;6:121. doi: 10.3389/fnagi.2014.00121. eCollection 2014. Review.

12.

Alzheimer's disease risk genes and mechanisms of disease pathogenesis.

Karch CM, Goate AM.

Biol Psychiatry. 2015 Jan 1;77(1):43-51. doi: 10.1016/j.biopsych.2014.05.006. Epub 2014 May 17. Review.

13.

LCAT deficiency does not impair amyloid metabolism in APP/PS1 mice.

Stukas S, Freeman L, Lee M, Wilkinson A, Ossoli A, Vaisman B, Demosky S, Chan J, Hirsch-Reinshagen V, Remaley AT, Wellington CL.

J Lipid Res. 2014 Aug;55(8):1721-9. doi: 10.1194/jlr.M049940. Epub 2014 Jun 20.

14.

Cognitive deficits and disruption of neurogenesis in a mouse model of apolipoprotein E4 domain interaction.

Adeosun SO, Hou X, Zheng B, Stockmeier C, Ou X, Paul I, Mosley T, Weisgraber K, Wang JM.

J Biol Chem. 2014 Jan 31;289(5):2946-59. doi: 10.1074/jbc.M113.497909. Epub 2013 Dec 9.

15.

Gene transfer of human Apoe isoforms results in differential modulation of amyloid deposition and neurotoxicity in mouse brain.

Hudry E, Dashkoff J, Roe AD, Takeda S, Koffie RM, Hashimoto T, Scheel M, Spires-Jones T, Arbel-Ornath M, Betensky R, Davidson BL, Hyman BT.

Sci Transl Med. 2013 Nov 20;5(212):212ra161. doi: 10.1126/scitranslmed.3007000.

16.
17.

Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid β peptide.

Hashimoto T, Serrano-Pozo A, Hori Y, Adams KW, Takeda S, Banerji AO, Mitani A, Joyner D, Thyssen DH, Bacskai BJ, Frosch MP, Spires-Jones TL, Finn MB, Holtzman DM, Hyman BT.

J Neurosci. 2012 Oct 24;32(43):15181-92. doi: 10.1523/JNEUROSCI.1542-12.2012.

18.

Molecular neuropathogenesis of Alzheimer's disease: an interaction model stressing the central role of oxidative stress.

Rodrigues R, Smith MA, Wang X, Perry G, Lee HG, Zhu X, Petersen RB.

Future Neurol. 2012 May;7(3):287-305.

19.

BACE1 levels by APOE genotype in non-demented and Alzheimer's post-mortem brains.

Decourt B, Gonzales A, Beach TG, Malek-Ahmadi M, Walker A, Sue L, Walker DG, Sabbagh MN.

Curr Alzheimer Res. 2013 Mar;10(3):309-15.

20.

Total ApoE and ApoE4 isoform assays in an Alzheimer's disease case-control study by targeted mass spectrometry (n=669): a pilot assay for methionine-containing proteotypic peptides.

Simon R, Girod M, Fonbonne C, Salvador A, Clément Y, Lantéri P, Amouyel P, Lambert JC, Lemoine J.

Mol Cell Proteomics. 2012 Nov;11(11):1389-403. doi: 10.1074/mcp.M112.018861. Epub 2012 Aug 23.

Supplemental Content

Support Center